10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2019 | |||
Consolidated Statements of Operations | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 19, 2020) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Revenue | $ 22,319,500 | 21,493,300 | 19,973,800 |
| Costs, expenses, and other: | |||
| Cost of sales | 4,721,200 | 4,681,700 | 4,447,700 |
| Research and development | 5,595,000 | 5,051,200 | 5,096,200 |
| Marketing, selling, and administrative | 6,213,800 | 5,975,100 | 5,982,400 |
| Acquired in-process research and development (Note 3) | 239,600 | 1,983,900 | 1,112,600 |
| Asset impairment, restructuring, and other special charges (Note 5) | 575,600 | 266,900 | 1,331,600 |
| Othernet, (income) expense (Note 18) | (291,600) | (145,600) | (301,500) |
| Costs, expenses, and other | 17,053,600 | 17,813,200 | 17,669,000 |
| Income before income taxes | 5,265,900 | 3,680,100 | 2,304,800 |
| Income taxes (Note 14) | 628,000 | 529,500 | 2,391,200 |
| Net income (loss) from continuing operations | 4,637,900 | 3,150,600 | (86,400) |
| Net income (loss) from discontinued operations (Note 19) | 3,680,500 | 81,400 | (117,700) |
| Net income (loss) | 8,318,400 | 3,232,000 | (204,100) |
| Earnings (loss) per share: | |||
| Earnings (loss) from continuing operations - basic (in usd per share) | 4.98 | 3.07 | (0.08) |
| Earnings (loss) from discontinued operations - basic (in usd per share) | 3.95 | 0.07 | (0.11) |
| Earnings (loss) per share - basic (in usd per share) | 8.93 | 3.14 | (0.19) |
| Earnings (loss) from continuing operations - diluted (in usd per share) | 4.96 | 3.05 | (0.08) |
| Earnings (loss) from discontinued operations - diluted (in usd per share) | 3.93 | 0.08 | (0.11) |
| Earnings (loss) per share - diluted (in usd per share) | 8.89 | 3.13 | (0.19) |
| Shares used in calculation of earnings (loss) per share: | |||
| Basic (in shares) | 931,059 | 1,027,721 | 1,052,023 |
| Diluted (in shares) | 935,684 | 1,033,667 | 1,052,023 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2019 | |||
Consolidated Statements of Comprehensive Income (Loss) | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 19, 2020) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Net income (loss) | $ 8,318,400 | 3,232,000 | (204,100) |
| Other comprehensive income (loss) from continuing operations: | |||
| Change in foreign currency translation gains (losses) | (89,900) | (429,600) | 362,900 |
| Change in net unrealized gains (losses) on securities | 34,400 | (8,800) | (181,300) |
| Change in defined benefit pension and retiree health benefit plans (Note 15) | (970,000) | 544,000 | (566,800) |
| Change in effective portion of cash flow hedges | 34,300 | ||
| Change in effective portion of cash flow hedges | (6,000) | 27,800 | |
| Other comprehensive income (loss) from continuing operations before income taxes | (991,200) | 99,600 | (357,400) |
| Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations | 151,000 | (30,300) | 402,700 |
| Net other comprehensive income (loss) | (783,400) | 83,600 | 174,500 |
| Comprehensive income (loss) | 7,535,000 | 3,315,600 | (29,600) |
| Operating Activities | |||
| Continuing Operations | |||
| Net other comprehensive income (loss) | (840,200) | 69,300 | 45,300 |
| Discontinued Operations | |||
| Net other comprehensive income (loss) | 56,800 | 14,300 | 129,200 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2019 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 19, 2020) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] | |||
| Cash Flows from Operating Activities | |||
| Net income (loss) | $ 8,318,400 | 3,232,000 | (204,100) |
| Adjustments to Reconcile Net Income (Loss) to Cash Flows from Operating Activities: | |||
| Gain related to disposal or sale | (309,800) | 0 | 0 |
| Depreciation and amortization | 1,232,600 | 1,609,000 | 1,567,300 |
| Change in deferred income taxes | 62,400 | 326,800 | (787,900) |
| Stock-based compensation expense | 312,400 | 279,500 | 281,300 |
| Acquired in-process research and development (Note 3) | 239,600 | 1,983,900 | 1,112,600 |
| Other non-cash operating activities, net | 348,700 | 472,000 | 441,500 |
| Other changes in operating assets and liabilities, net of acquisitions and divestitures: | |||
| Receivables(increase) decrease | (127,200) | (996,700) | (357,000) |
| Inventories(increase) decrease | (258,700) | 7,800 | (253,900) |
| Other assets(increase) decrease | (602,300) | (980,000) | (590,100) |
| Income taxes payableincrease (decrease) | (221,300) | (125,300) | 3,489,600 |
| Accounts payable and other liabilitiesincrease (decrease) | (477,700) | (284,500) | 916,300 |
| Net Cash Provided by Operating Activities | 4,836,600 | 5,524,500 | 5,615,600 |
| Cash Flows from Investing Activities | |||
| Purchases of property and equipment | (1,033,900) | (1,210,600) | (1,076,800) |
| Proceeds from sales and maturities of short-term investments | 136,600 | 2,552,500 | 4,852,500 |
| Purchases of short-term investments | (42,700) | (112,200) | (3,389,700) |
| Proceeds from sales of noncurrent investments | 609,800 | 3,509,500 | 2,586,000 |
| Purchases of noncurrent investments | (247,500) | (837,900) | (4,611,600) |
| Purchases of in-process research and development | (319,600) | (1,807,600) | (1,086,800) |
| Cash paid for acquisitions, net of cash acquired (Note 3 and 19) | (6,917,700) | 0 | (882,100) |
| Other investing activities, net | (248,700) | (187,700) | (175,100) |
| Net Cash Provided by (Used for) Investing Activities | (8,082,900) | 1,906,000 | (3,783,600) |
| Cash Flows from Financing Activities | |||
| Dividends paid | (2,409,800) | (2,311,800) | (2,192,100) |
| Net change in short-term borrowings | 995,400 | (2,197,900) | 1,397,500 |
| Proceeds from issuance of long-term debt | 6,556,400 | 2,477,700 | 2,232,000 |
| Repayments of long-term debt | (2,866,400) | (1,009,100) | (630,600) |
| Purchases of common stock | (4,400,000) | (4,150,700) | (299,800) |
| Net proceeds from Elanco initial public offering (Note 19) | 0 | 1,659,700 | 0 |
| Other financing activities, net | (200,100) | (372,800) | (364,400) |
| Net Cash Provided by (Used for) Financing Activities | (2,324,500) | (5,904,900) | 142,600 |
| Effect of exchange rate changes on cash and cash equivalents | (89,900) | (63,600) | (20,500) |
| Net increase (decrease) in cash and cash equivalents | (5,660,700) | 1,462,000 | 1,954,100 |
| Cash and cash equivalents at beginning of year (includes $677.5 (2019), $324.4 (2018), and $258.8 (2017) of discontinued operations) | 7,998,200 | 6,536,200 | |
| Cash and Cash Equivalents at End of Year (includes $677.5 (2018) and $324.4 (2017) of discontinued operations) | 2,337,500 | 7,320,700 | |
| Cash and Cash Equivalents at End of Year (includes $677.5 (2018) and $324.4 (2017) of discontinued operations) | 7,998,200 | 6,536,200 | |
| Disposal Group Classification | |||
| Disposal Group, Disposed of by Sale, Not Discontinued Operations | |||
| Disposal Group Name | |||
| Elanco | |||
| Gain related to disposal or sale | (3,680,500) | 0 | 0 |
| Cash distributed to Elanco upon disposition | (374,000) | 0 | 0 |
| Legacy Antibiotic Medicines and a Manufacturing Facility in Suzhou, China | |||
| Gain related to disposal or sale | (309,800) | 0 | 0 |
| Cash received for sale of antibiotic business in China | 354,800 | 0 | 0 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ELI LILLY & CO | ||
Ticker: LLY Fiscal Year: 2019 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2019 10-K (Filed: Feb 19, 2020) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2019 | Dec 31, 2018 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents (Note 7) | $ 7,998,200 | |
| Cash and cash equivalents (Note 7) | 2,337,500 | 7,320,700 |
| Short-term investments (Note 7) | 101,000 | 88,200 |
| Accounts receivable, net of allowances of $22.4 (2019) and $24.1 (2018) | 4,547,300 | 4,593,900 |
| Other receivables | 994,200 | 1,182,900 |
| Inventories (Note 6) | 3,190,700 | 3,098,100 |
| Prepaid expenses and other | 2,538,900 | 2,036,700 |
| Current assets of discontinued operations (Note 19) | 0 | 2,229,100 |
| Total current assets | 13,709,600 | 20,549,600 |
| Investments (Note 7) | 1,962,400 | 2,005,400 |
| Goodwill (Note 8) | 3,679,400 | 1,366,600 |
| Other intangibles, net (Note 8) | 6,618,000 | 1,068,000 |
| Deferred tax assets (Note 14) | 2,572,600 | 2,613,700 |
| Property and equipment, net (Note 9) | 7,872,900 | 7,996,100 |
| Operating lease assets (Note 10) | 532,100 | 530,000 |
| Other noncurrent assets | 2,339,100 | 1,824,900 |
| Noncurrent assets of discontinued operations (Note 19) | 0 | 6,484,100 |
| Total assets | 39,286,100 | 43,908,400 |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Short-term borrowings and current maturities of long-term debt (Note 11) | 1,499,300 | 1,102,200 |
| Accounts payable | 1,405,300 | 1,207,100 |
| Employee compensation | 915,500 | 955,600 |
| Sales rebates and discounts | 4,933,600 | 4,849,500 |
| Dividends payable | 671,500 | 650,800 |
| Income taxes payable (Note 14) | 160,600 | 393,400 |
| Other current liabilities | 2,189,400 | 2,036,700 |
| Current liabilities of discontinued operations (Note 19) | 0 | 692,800 |
| Total current liabilities | 11,775,200 | 11,888,100 |
| Other Liabilities | ||
| Long-term debt (Note 11) | 13,817,900 | 9,196,400 |
| Noncurrent operating lease liabilities (Note 10) | 486,700 | |
| Accrued retirement benefits (Note 15) | 3,698,200 | 2,802,200 |
| Long-term income taxes payable (Note 14) | 3,607,200 | 3,700,000 |
| Other noncurrent liabilities | 1,014,300 | 1,357,600 |
| Deferred tax liabilities (Note 14) | 2,187,500 | 1,312,700 |
| Noncurrent liabilities of discontinued operations (Note 19) | 0 | 2,742,300 |
| Total other liabilities | 24,811,800 | 21,111,200 |
| Commitments and Contingencies (Note 16) | ||
| Eli Lilly and Company Shareholders' Equity (Notes 12 and 13) | ||
| Common stockno par value Authorized shares: 3,200,000 Issued shares: 958,056 (2019) and 1,057,639 (2018) | 598,800 | 661,000 |
| Additional paid-in capital | 6,685,300 | 6,583,600 |
| Retained earnings | 4,920,400 | 11,395,900 |
| Employee benefit trust | (3,013,200) | (3,013,200) |
| Accumulated other comprehensive loss (Note 17) | (6,523,600) | (5,729,200) |
| Cost of common stock in treasury | (60,800) | (69,400) |
| Total Eli Lilly and Company shareholders' equity | 2,606,900 | 9,828,700 |
| Noncontrolling interests | 92,200 | 1,080,400 |
| Total equity | 2,699,100 | 10,909,100 |
| Total liabilities and equity | 39,286,100 | 43,908,400 |
| External Links | |
| ELI LILLY & CO (LLY) Fiscal Year 2019 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |